Zobrazeno 1 - 10
of 62
pro vyhledávání: '"Kiyotoshi Imai"'
Autor:
Shinichi Kako, Fumihiko Hayakawa, Koichi Miyamura, Junji Tanaka, Kiyotoshi Imai, Junya Kanda, Satoko Morishima, Naoyuki Uchida, Noriko Doki, Kazuhiro Ikegame, Yukiyasu Ozawa, Satoru Takada, Noriko Usui, Shigeki Ohtake, Hitoshi Kiyoi, Itaru Matsumura, Yasushi Miyazaki, Tatsuo Ichinohe, Takahiro Fukuda, Yoshiko Atsuta, Yoshinobu Kanda
Publikováno v:
Transplantation and cellular therapy. 28(3)
An HLA-matched relative is the first-choice donor for patients with Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL) in first complete remission (CR1). The most promising alternative donor is thought to be an HLA-matched unrel
Autor:
Heiwa Kanamori, Tohru Murayama, Yasushi Miyazaki, Yukiyasu Ozawa, Yoshiko Atsuta, Tatsuo Ichinohe, Junichi Mukae, Tadakazu Kondo, Noriko Usui, Yoshinori Tanaka, Kiyotoshi Imai, Junji Tanaka, Shuichi Ota, Fumihiko Hayakawa, Satoshi Nishiwaki, Shigeki Ohtake, Takahiro Fukuda, Shuichi Mizuta, Itaru Matsumura, Shinichi Kako, Shingo Kurahashi, Hitoshi Kiyoi, Toru Sakura
Publikováno v:
International journal of hematology. 114(5)
The optimal treatment for Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL) in first complete remission (CR1) has not been established in the high-intensity chemotherapy era. The outcomes of patients with Ph-negative ALL who un
Autor:
Yoshihiro Hatta, Akiko Saito, Maki Hagihara, Itaru Matsumura, Yuichi Yahagi, Tsutomu Takahashi, Yoshiko Atsuta, Hiroatsu Iida, Naoki Mori, Isamu Sugiura, Koichiro Minauchi, Fumihiko Hayakawa, Akihiro Hirakawa, Kiyotoshi Imai, Tohru Murayama, Takeshi Saito, Yasushi Miyazaki, Etsuko Yamazaki, Hitoshi Kiyoi, Toru Sakura
Publikováno v:
International journal of hematology. 113(3)
This phase 1/2 study aimed to identify the maximum tolerated dose, the recommended phase 2 dose (RP2D), and efficacy of the clofarabine, etoposide, and cyclophosphamide combination regimen in adult patients with relapsed/refractory acute lymphoblasti
Autor:
Yasutaka Aoyama, Yasushi Miyazaki, Kazuhiko Kakihana, Kiyotoshi Imai, Yasunori Ueda, Tomoki Naoe, Kazunori Ohnishi, Shuichi Mizuta, Nobuaki Dobashi, Shigeki Ohtake, Hideki Akiyama, Keitaro Matsuo, Isamu Sugiura, Shin Fujisawa, Yoshihiro Hatta, Yasushi Onishi, Tomoya Maeda
Publikováno v:
American Journal of Hematology. 92:367-374
This study investigated the efficacy of imatinib based therapy with intensified consolidation therapy in patients with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) to prevent early relapse. We conducted a phase II trial of
Autor:
Yoshinori Tanaka, Naoyuki Uchida, Heiwa Kanamori, Noriko Doki, Shigeki Ohtake, Toru Sakura, Kazuhiro Ikegame, Shuichi Ota, Fumihiko Hayakawa, Yasushi Miyazaki, Shinichi Kako, Shingo Kurahashi, Shuichi Mizuta, Itaru Matsumura, Yoshiko Atsuta, Satoshi Nishiwaki, Tohru Murayama, Tatsuo Ichinohe, Noriko Usui, Takahiro Fukuda, Hitoshi Kiyoi, Kiyotoshi Imai, Junji Tanaka
Publikováno v:
Blood. 134:4589-4589
[Background] We previously demonstrated that allogeneic hematopoietic stem cell transplantation (HSCT) in the first complete remission (CR1) was recommended for adult patients wih Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (AL
Autor:
Yutaka Tsutsumi, Shuichi Ota, Takahiro Nagashima, Akio Mori, Kohei Kasahara, Kiyotoshi Imai, Daisuke Hidaka, Kaoru Kahata, Masao Nakagawa, Hajime Kobayashi, Yasutaka Kakinoki, Chikara Shimizu, Takuto Miyagishima, Hiroshi Iwasaki, Masahiro Onozawa, Hajime Sakai, Souichi Shiratori, Junichi Sugita, Eiko Hayase, Yoshihito Haseyama, Junichi Hashiguchi, Hideki Goto, Satoshi Yamamoto, Takeshi Kondo, Takanori Teshima, Daigo Hashimoto, Kohei Okada, Shinichi Fujisawa, Mitsutoshi Kurosawa, Naohiro Miyashita, Tomoyuki Endo, Toshimichi Ishihara
Publikováno v:
Clinical lymphoma, myelomaleukemia. 18(11)
The association between Wilms tumor 1 (WT1) expression, genetic abnormalities and homozygous single polymorphism (SNP) in WT1 gene was evaluated in 252 acute myelogenous leukemia (AML) patients. WT1 expression correlated with prognostic genetic abnor
Autor:
Tetsuya Eto, Kazuteru Ohashi, Shuichi Taniguchi, Toru Sakura, Kiyotoshi Imai, Masatsugu Tanaka, Koichi Miyamura, Takahiro Fukuda, Tokiko Nagamura-Inoue, Yoshiko Atsuta, Hiroatsu Ago, Naoyuki Uchida, Seitaro Terakura, Shinichiro Mori, Shinichiro Okamoto
Publikováno v:
Biology of Blood and Marrow Transplantation. 21(3):517-525
We retrospectively compared the transplantation outcomes for patients 50 years or older who received umbilical cord blood transplantation (UCBT) with those who received unrelated bone marrow transplantation (UBMT) for hematologic malignancies. A tota
Autor:
Kiyotoshi, Imai
Publikováno v:
[Rinsho ketsueki] The Japanese journal of clinical hematology. 58(10)
Most patients with adult acute lymphoblastic leukemia (ALL) undergo relapse, despite the achievement of complete remission with chemotherapy. Among patients with relapsed or refractory ALL, remission rates are 18-44% with the use of standard salvage
Autor:
Yoshiko Atsuta, Yasuhiko Miyata, Maho Ishikawa, Tetsuya Fukuda, Noriko Usui, Shinichi Kobayashi, Tetsuzo Tauchi, Hiroshi Gomyo, Kazunori Ohnishi, Yasushi Miyazaki, Kohshi Ohishi, Naoto Takahashi, Katsumichi Fujimaki, Hitoshi Suzushima, Kiyotoshi Imai, Koichi Miyamura, Takaaki Miyake, Yoshio Saburi, Tomoki Naoe, Kensuke Usuki, Satoru Takada, Itaru Matsumura, Yukio Kobayashi, Osamu Sasaki, Shigeki Ohtake, Hitoshi Kiyoi, Yoshihiro Hatta, Toru Kiguchi, Kunio Kitamura, Yosuke Minami, Kazuto Togitani, Hideki Mitsui
Publikováno v:
International journal of hematology. 107(2)
The objective of this prospective clinical trial (JALSG-STIM213, UMIN000011971) was to evaluate treatment-free remission (TFR) rates after discontinuation of imatinib in chronic myeloid leukemia (CML). CML patients who received imatinib treatment for
Autor:
Kiyotoshi, Imai
Publikováno v:
[Rinsho ketsueki] The Japanese journal of clinical hematology. 58(5)
Acute lymphoblastic leukemia (ALL) is seen in both children and adults, but its incidence peaks between 2 and 5 years and also increases in the older population. Although most children can be cured, the prognosis of adults with ALL remains poor. Rece